ON THIS PAGE: You will find information about how many people learn they have CML each year and some general survival information. Remember, survival rates depend on several factors. To see other page in this guide, use the colored boxes on the right side of your screen, or click “Next” as the bottom.
This year, an estimated 5,920 people of all ages (3,420 men and boys and 2,500 women and girls) in the United States will be diagnosed with CML. Most of these will be adults; CML is rare in children. It is estimated that 610 deaths (340 men and boys and 270 women and girls) will occur this year.
The five-year survival rate (the percentage of people who survive at least five years after the cancer is detected, excluding those who die from other diseases) for people with CML depends on the phase of the disease , other biologic characteristics of the CML, and the disease’s response to treatment. The pace of CML research is rapid, with several drug approvals in the past decade. It is important to note that many of the new drugs for CML work very well, but were developed recently so the average survival rates are not yet known for people with CML who take these drugs. In one study of patients with CML who were taking the drug imatinib (Gleevec), researchers found that 90% lived at least five years.
Cancer survival statistics should be interpreted with caution. These estimates are based on data from thousands of people with this type of cancer in the United States each year, but the actual risk for a particular individual may differ. It is not possible to tell a person how long he or she will live with CML. Because survival statistics are measured in five-year intervals, they may not represent recent significant advances made in the treatment and diagnosis of CML. Learn more about understanding statistics .
Statistics adapted from the American Cancer Society's publication, Cancer Facts and Figures 2013.
Choose “Next” (below, right) to continue reading this guide, or use the colored boxes located on the right side of your screen to visit any section.